---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-23-000063"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T09:59:41.808542+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Supernus announces Q3 2023 earnings release and call on Nov 8

## Summary
- Earnings results after market close on Nov 8, 2023; call at 4:30 p.m. ET.
- President/CEO Jack Khattar and CFO Tim Dec to host conference call.
- No financial results disclosed; this is a scheduling announcement.

## SEC filing metadata
- accession: 0001356576-23-000063
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000063/0001356576-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000063/supn-20231025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-23-000063
- JSON: https://secwatch.observer/filing/0001356576-23-000063.json
- Plain text: https://secwatch.observer/filing/0001356576-23-000063.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. reported financial results for the third quarter of 2023.
  - Period: the third quarter of 2023
  - Result: reported results
  source text: Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the third quarter of 2023 after the market closes on Wednesday, November 8, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000063/0001356576-23-000063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.